ACCO Brands Corporation
NYSE:ACCOBusiness Equipment & Supplies
+$0.05 today
- Market cap
- $517.11M
- Beta
- 1.21
- P/E (TTM)
- 4.9
- EPS (TTM)
- $0.80
- Dividend yield
- 7.70%
Volume 1.77M
Average 1.07M
ACCO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
ACCO Brands CorporationNYSE: ACCO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0. Over 3 fiscal years it compounded at -5.8% a year.
Context
- Research & development amounted to 1.4% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 22M USD
- Year-over-year change
- -4.3%
- 4-year CAGR
- -4.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22M | -4.3% |
| FY2024 | 2024-12-31 | 23M | -10.9% |
| FY2023 | 2023-12-31 | 25.8M | -1.9% |
| FY2022 | 2022-12-31 | 26.3M | -1.1% |
| FY2021 | 2021-12-31 | 26.6M | — |
Research & Development vs competitors
How ACCO compares with its peers on the latest reported figures
- ACCO's LTM Mar 2026 research & development of $0 is the 3rd highest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of -100.0% is the 3rd highest of 4, against a peer median of +7.0%.
- Research & development amounts to 0.0% of revenue for ACCO, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $36.71M | +16.0% | +18.4% | 57.8% | |
| LTM Mar 2026 | $4.6M | +7.0% | -4.3% | 1.2% | |
| LTM Mar 2026 | $0 | -100.0% | -5.8% | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
SBCSBC Medical Group Holdings Incorporated | LTM Mar 2026 | $0 | — | — | 0.0% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Feb 2026 | $0 | — | — | 0.0% | |
| LTM Apr 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ACCO) | $0 | +7.0% | +7.1% | 0.0% | |
Competitors are the stored peer set for ACCO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.03B | 1.95B | 1.83B | 1.67B | 1.52B |
| Cost of Revenue | 1.41B | 1.4B | 1.23B | 1.11B | 1.07B |
| Gross Profit | 614.9M | 552.3M | 598.3M | 555.4M | 454.9M |
| Gross Margin | 30.4% | 28.4% | 32.6% | 33.3% | 29.8% |
| Research & Development | 26.6M | 26.3M | 25.8M | 23M | 22M |
| Selling, General & Admin | 392.6M | 376.7M | 395.3M | 371.8M | 324.7M |
| Operating Expenses | 463.9M | 517.5M | 553.6M | 592.4M | 346.7M |
| Depreciation & Amortization | 85.7M | 79.4M | 76.1M | 73.1M | 72.8M |
| EBITDA | 243.4M | 139.9M | 121.6M | 38.4M | 167.7M |
| EBITDA Margin | 12.0% | 7.2% | 6.6% | 2.3% | 11.0% |
| Operating Income | 151M | 34.8M | 44.7M | (37M) | 108.2M |
| Operating Margin | 7.5% | 1.8% | 2.4% | -2.2% | 7.1% |
| Interest Income | 1.9M | 8.3M | 7.1M | 7.5M | 9.4M |
| Interest Expense | 46.3M | 45.6M | 58.6M | 52.6M | 45.8M |
| Other Income / Expenses | (39.6M) | (19.9M) | (57.8M) | (50.3M) | (59.1M) |
| Income Before Tax | 111.4M | 14.9M | (13.1M) | (87.3M) | 49.1M |
| Pre-Tax Margin | 5.5% | 0.8% | -0.7% | -5.2% | 3.2% |
| Income Tax Expense | 9.5M | 28.1M | 8.7M | 14.3M | 7.8M |
| Net Income | 101.9M | (13.2M) | (21.8M) | (101.6M) | 41.3M |
| Net Margin | 5.0% | -0.7% | -1.2% | -6.1% | 2.7% |
| EPS (Basic) | 1.07 | (0.14) | (0.23) | (1.06) | 0.45 |
| EPS (Diluted) | 1.05 | (0.14) | (0.23) | (1.06) | 0.44 |
| Weighted Avg Shares | 95.5M | 95.3M | 95.3M | 95.6M | 92.1M |
| Weighted Avg Shares (Diluted) | 97.1M | 95.3M | 95.3M | 95.6M | 94M |
ACCO Brands Corporation
NYSE:ACCO
Intrinsic Alpha fair value
Locked
Current Price
$5.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.